Home/Pipeline/Holoclar

Holoclar

Limbal Stem Cell Deficiency (LSCD)

ApprovedActive

Key Facts

Indication

Limbal Stem Cell Deficiency (LSCD)

Phase

Approved

Status

Active

Company

Holostem Tarapie Avanzate

About Holostem Tarapie Avanzate

Holostem is a pioneering, commercial-stage Italian biotech specializing in epithelial stem cell-based regenerative medicine. The company has achieved a significant milestone with its lead product, Holoclar, receiving full marketing authorization from the European Commission for treating limbal stem cell deficiency. Operating from within the University of Modena's Centre for Regenerative Medicine, Holostem leverages a strong academic foundation to advance its pipeline of cell and gene therapies, recently gaining recognition as an Important Project of Common European Interest (IPCEI).

View full company profile

Therapeutic Areas

Ophthalmology Genetic Disorders

Other Limbal Stem Cell Deficiency (LSCD) Drugs

Drug	Company	Phase	Status
CSB-001	Claris Bio	Unknown	Active
KPI-012	Kala Pharmaceuticals	Preclinical	Research/Development